Slide 3
Image is not available
A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
Slide 1
Image is not available
Committed to building a pharmaceutical
ecosystem focused on delivering solutions in
an open and collaborative setting for
the benefit of all stakeholders
To fulfill unmet clinical needs
Slide 2
Image is not available
Providing competitive
products and services
To enable the more effective diagnosis
and treatment, whilst enhancing clinical
practice to the ultimate benefit of the patient
previous arrow
next arrow

Innovation

Bio-technology incubation platform

Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products. 

go

INNOVATION

Business

Commercialization platform

Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.

go

BUSINESS

Cardio-cerebrovascular
and gastroenterology

Dermatology
and medical aesthetic

Ophthalmology

Southeast Asia Business

News

2024-06-25

China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China

On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China. This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo.   This trial is a randomized, double-blind, placebo-controlled phase III clinical trial evaluating the efficacy and safety of ruxolitinib cream in the treatment of atopic dermatitis in Chinese patients. The trial aims to provide more medical evidence to support the Product’s marketing application in China. The trial, led by Professor Shi Yuling, Vice President of Shanghai Skin Disease Hospital, will be conducted in 20 sites nationwide aiming to enroll approximately 192 atopic dermatitis patients. […]

go
战略合作&联系我们

Partnering

We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.

go

Contact Us

If you are interested in joining us, or curious about our business and products, please feel free to contact us.

go